financetom
Business
financetom
/
Business
/
ING Comments on Canadian Dollar
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ING Comments on Canadian Dollar
Feb 28, 2025 4:38 AM

07:18 AM EST, 02/28/2025 (MT Newswires) -- USD/CAD rallied Thursday as United States President Donald Trump outlined a tariff schedule that explicitly includes duties on Canada and Mexico from next Tuesday, said ING.

The pair is currently embedding around 2% of risk premium, according to the bank's short-term fair value model. That is above the 1.5 standard deviation, but still well below the nearly 4% peak risk premium that was embedded in USD/CAD on Feb. 3.

Back then, ING published a note to discuss its view on the Canadian dollar (CAD or loonie) under the assumption that 25% tariffs would go ahead. Most of those considerations stand, and depending on how long tariffs remain in place, a move to 1.50 is a definite possibility, stated the bank.

The difference this time is that markets are treating Trump's tariff threat with more skepticism, refusing to price in the full tariff effect and partly betting on another last-minute deal, pointed out ING.

The bank still sees upside risks to USD/CAD on Friday unless there are any reports of a de-escalation. ING sees 1.45 as the level that would mark a shift to markets pricing in the tariff risk as a base case.

If duties are levied on Tuesday, then ING will look at 1.480 as the key resistance to be tested.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
Jan 28, 2025
Jan 28 (Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of chronic kidney disease and the organ's failure, and death due to heart problems in adults with type 2 diabetes. Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same...
Market Chatter: Nvidia Short Sellers Amass $6.6 Billion in Profits Amid Frenzy Over DeepSeek
Market Chatter: Nvidia Short Sellers Amass $6.6 Billion in Profits Amid Frenzy Over DeepSeek
Jan 28, 2025
03:06 PM EST, 01/28/2025 (MT Newswires) -- Bets against Nvidia ( NVDA ) amid a surge in interest for Chinese artificial intelligence app DeepSeek yielded one-day gains of about $6.6 billion for short sellers, Reuters reported Tuesday, citing data analytics firm Ortex. Short positions in Broadcom ( AVGO ) resulted in more than $2 billion in profits, the report added....
BRIEF-QMSK Technology Co Ltd Files For U.S. IPO - SEC FILING
BRIEF-QMSK Technology Co Ltd Files For U.S. IPO - SEC FILING
Jan 28, 2025
Jan 28 (Reuters) - QMSK Technology Co Ltd: * QMSK TECHNOLOGY CO LTD: FILES FOR U.S. IPO * QMSK TECHNOLOGY CO., LTD: EXPECT IPO OFFERING PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE * QMSK TECHNOLOGY CO: EXPECT US IPO PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE...
Tower Semiconductor Analyst Sees 'Attractive' Buying Opportunity Following DeepSeek Selloff
Tower Semiconductor Analyst Sees 'Attractive' Buying Opportunity Following DeepSeek Selloff
Jan 28, 2025
Benchmark analyst Cody Acree named Tower Semiconductor ( TSEM ) Inc. among recommended oversold names following Monday’s market rout, which was triggered by DeepSeek’s announcement of its advanced language model. Monday’s Selloff: Chinese AI lab DeepSeek unveiled a new large language model reportedly meeting or exceeding leading competitors’ performance at a fraction of the cost. The claims, though met with...
Copyright 2023-2025 - www.financetom.com All Rights Reserved